PKO Investment Management Joint Stock Co Invests $1.08 Million in Stryker Co. (NYSE:SYK)

PKO Investment Management Joint Stock Co purchased a new position in shares of Stryker Co. (NYSE:SYK - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 3,000 shares of the medical technology company's stock, valued at approximately $1,080,000.

Several other hedge funds have also recently modified their holdings of SYK. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Stryker in the fourth quarter valued at about $25,000. Capital A Wealth Management LLC acquired a new stake in Stryker in the fourth quarter valued at about $26,000. Rakuten Securities Inc. boosted its holdings in Stryker by 618.2% in the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock valued at $28,000 after purchasing an additional 68 shares in the last quarter. Centricity Wealth Management LLC acquired a new position in Stryker during the 4th quarter worth approximately $30,000. Finally, BankPlus Trust Department purchased a new position in shares of Stryker during the 4th quarter worth approximately $33,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the completion of the sale, the director now directly owns 3,417,326 shares of the company's stock, valued at approximately $1,288,195,208.96. The trade was a 5.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 5.20% of the company's stock.

Stryker Price Performance

NYSE:SYK traded up $0.51 during trading hours on Friday, reaching $382.86. 1,993,145 shares of the company traded hands, compared to its average volume of 1,342,850. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The firm's 50-day moving average is $368.57 and its 200-day moving average is $376.25. The stock has a market cap of $146.13 billion, a P/E ratio of 49.34, a P/E/G ratio of 2.93 and a beta of 0.93. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, beating analysts' consensus estimates of $2.73 by $0.11. The business had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The business's revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter last year, the company earned $2.50 earnings per share. Equities research analysts expect that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Monday, June 30th will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.88%. The ex-dividend date of this dividend is Monday, June 30th. Stryker's dividend payout ratio is presently 45.41%.

Analyst Ratings Changes

SYK has been the topic of a number of analyst reports. Evercore ISI decreased their price target on Stryker from $400.00 to $390.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. Barclays boosted their target price on shares of Stryker from $418.00 to $443.00 and gave the stock an "overweight" rating in a research report on Monday, February 10th. Sanford C. Bernstein set a $450.00 price target on shares of Stryker in a research note on Monday, May 5th. JMP Securities reiterated a "market perform" rating on shares of Stryker in a research note on Monday, May 5th. Finally, BTIG Research set a $403.00 price objective on shares of Stryker and gave the stock a "buy" rating in a report on Monday, April 14th. Five analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $427.30.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.